Celcuity Shares Surge to Record High on Accelerated FDA Review

Celcuity Inc. saw its stock price climb to an unprecedented peak of $55.58 on Friday, cementing a remarkable year-to-date gain of 264.54%. This powerful rally was ignited by the announcement that the U.S. Food and Drug Administration (FDA) has granted an accelerated review pathway for the company’s investigational cancer drug, Gedatolisib.

The catalyst for this surge came on August 27th, when the regulatory agency accepted the New Drug Application for Gedatolisib into its Real-Time Oncology Review (RTOR) program. This prestigious designation is reserved for therapies demonstrating substantial clinical improvements over existing treatment options.

Supporting this regulatory advancement were compelling results from the pivotal Phase 3 VIKTORIA-1 trial. The data revealed that Gedatolisib administered as a triple therapy achieved a dramatic 76% reduction in the risk of disease progression or death for patients with PIK3CA wild-type tumors. Even the doublet therapy regimen demonstrated a robust 67% risk reduction.

Adding to the positive momentum, significant insider buying activity has emerged. Chief Executive Officer Brian F. Sullivan substantially increased his stake in the company on September 2nd, acquiring 104,340 common shares and warrants at $8.05 per unit. This transaction brings his total holdings to 1,370,199 shares, serving as a strong vote of confidence in Celcuity’s future prospects. Institutional investors are following suit, with Nuveen LLC establishing a new position of 69,587 shares valued at approximately $704,000 on September 4th.

Should investors sell immediately? Or is it worth buying Celcuity?

Financially, the company has positioned itself for the long term despite reporting a second-quarter loss of $1.04 per share, which was wider than the anticipated $0.88 loss. In a strategic move during August, Celcuity successfully secured $287 million through public offerings. This substantial capital infusion extends the company’s operational runway well into 2027.

The market opportunity for Celcuity appears significant, with the addressable market for second-line therapy in this specific patient population estimated at approximately $5 billion. With patent protection extending to 2042 and the accelerated FDA review now in place, the company appears well-positioned for sustained long-term growth.

Market experts maintain optimistic outlooks, with price targets ranging between $60 and $79 per share, even as the stock is currently considered technically overbought. The investment community now awaits the full data set from the VIKTORIA-1 study, which is scheduled for presentation at a medical conference later this year.